IL186750A0 - Pteridines useful as hcv inhibitors and methods for the preparation thereof - Google Patents

Pteridines useful as hcv inhibitors and methods for the preparation thereof

Info

Publication number
IL186750A0
IL186750A0 IL186750A IL18675007A IL186750A0 IL 186750 A0 IL186750 A0 IL 186750A0 IL 186750 A IL186750 A IL 186750A IL 18675007 A IL18675007 A IL 18675007A IL 186750 A0 IL186750 A0 IL 186750A0
Authority
IL
Israel
Prior art keywords
preparation
methods
hcv inhibitors
pteridines
useful
Prior art date
Application number
IL186750A
Other versions
IL186750A (en
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of IL186750A0 publication Critical patent/IL186750A0/en
Publication of IL186750A publication Critical patent/IL186750A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL186750A 2005-05-12 2007-10-18 Pteridines, uses thereof in the preparation of medicaments for inhibiting hcv replication, pharmaceutical compositions and combinations comprising them IL186750A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68039305P 2005-05-12 2005-05-12
EP05106212 2005-07-07
EP06075854 2006-04-06
PCT/EP2006/062289 WO2006120251A1 (en) 2005-05-12 2006-05-12 Pteridines useful as hcv inhibitors and methods for the preparation thereof

Publications (2)

Publication Number Publication Date
IL186750A0 true IL186750A0 (en) 2008-02-09
IL186750A IL186750A (en) 2014-08-31

Family

ID=36593103

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186750A IL186750A (en) 2005-05-12 2007-10-18 Pteridines, uses thereof in the preparation of medicaments for inhibiting hcv replication, pharmaceutical compositions and combinations comprising them

Country Status (14)

Country Link
US (5) US20090156595A1 (en)
EP (1) EP1881834B1 (en)
JP (1) JP5464685B2 (en)
KR (1) KR20080005978A (en)
AR (1) AR056347A1 (en)
AT (1) ATE554772T1 (en)
AU (1) AU2006245675B2 (en)
BR (1) BRPI0609101A2 (en)
CA (1) CA2608326C (en)
ES (1) ES2386461T3 (en)
IL (1) IL186750A (en)
MX (1) MX2007014081A (en)
PL (1) PL1881834T3 (en)
WO (1) WO2006120251A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577745C (en) * 2004-09-30 2012-11-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
DK1869037T3 (en) * 2005-03-25 2011-10-24 Tibotec Pharm Ltd Heterobicyclic inhibitors of HVC
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
CN102702194A (en) 2005-12-21 2012-10-03 雅培制药有限公司 Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
WO2007076034A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
US20090318456A1 (en) * 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
TWI399380B (en) 2006-12-20 2013-06-21 Abbott Lab Anti-viral compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EA019295B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Synthesis of purine nucleosides and process for preparing them
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US20120316184A1 (en) * 2010-02-24 2012-12-13 Syngenta Crop Protection Llc Novel microbicides
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
JP2013527145A (en) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー Stereoselective synthesis of phosphorus-containing activators
EP2609923B1 (en) 2010-03-31 2017-05-24 Gilead Pharmasset LLC Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
AR084044A1 (en) 2010-11-30 2013-04-17 Pharmasset Inc 2’-ESPIRO-NUCLEOSID COMPOUNDS
JP6073897B2 (en) 2011-09-16 2017-02-01 ギリアド ファーマセット エルエルシー Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2771458T3 (en) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
PL3650014T3 (en) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3097102B1 (en) 2015-03-04 2017-10-18 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN107501173B (en) * 2017-08-17 2020-07-24 武汉桀升生物科技有限公司 Method for synthesizing 4-alkylamino pyridine under mild condition
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751517B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202115056A (en) 2019-06-28 2021-04-16 美商基利科學股份有限公司 Processes for preparing toll-like receptor modulator compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789496A (en) * 1971-10-05 1973-03-29 S M B Anciens Ets J Muelberger
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ATE277929T1 (en) 1998-12-28 2004-10-15 4 Aza Bioscience Nv IMMUNOSUPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
US7087399B1 (en) * 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
IL150420A0 (en) 1999-12-28 2002-12-01 Pharmacopeia Inc Pyrimidine and triazine kinase inhibitors
HUP0302173A2 (en) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PE20021011A1 (en) 2001-03-23 2003-02-01 Bayer Corp QUINAZOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
JP2003321472A (en) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk inhibitor
EP1485381B8 (en) 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine as inhibitors of protein kinases
EP1485376B1 (en) 2002-03-15 2007-06-27 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
DE60332433D1 (en) 2002-03-15 2010-06-17 Vertex Pharma AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
KR100516434B1 (en) 2002-04-04 2005-09-22 (주) 비엔씨바이오팜 6-(4-substituted-anilino)pyrimidine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
US7491367B2 (en) * 2002-06-04 2009-02-17 Applera Corporation System and method for providing a standardized state interface for instrumentation
AU2003260072A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Antagonists of chemokine receptors
US20040132730A1 (en) 2002-09-10 2004-07-08 Jonathan Axon Inhibitors of TGFbeta
WO2004048930A2 (en) * 2002-11-22 2004-06-10 Scios, Inc. METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY
AU2003291149A1 (en) 2002-11-22 2004-06-18 Scios, Inc. USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CA2520465A1 (en) * 2003-03-28 2004-10-14 Scios Inc. Bi-cyclic pyrimidine inhibitors of tgf.beta.
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
JP5015769B2 (en) 2004-06-04 2012-08-29 バイオニケ ライフ サイエンシーズ インコーポレイテッド Use of imatinib to treat liver disease and viral infection
CA2577745C (en) * 2004-09-30 2012-11-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
WO2006105222A2 (en) 2005-03-25 2006-10-05 Scios Inc. Carboxamide inhibitors of tgfb
WO2006105063A1 (en) 2005-03-25 2006-10-05 Scios Inc. Heterobicylic inhibitors of tgfbeta
DK1869037T3 (en) 2005-03-25 2011-10-24 Tibotec Pharm Ltd Heterobicyclic inhibitors of HVC
TW200716631A (en) * 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS

Also Published As

Publication number Publication date
JP5464685B2 (en) 2014-04-09
US9290502B2 (en) 2016-03-22
CA2608326A1 (en) 2006-11-16
CA2608326C (en) 2015-11-10
AU2006245675B2 (en) 2011-04-14
AR056347A1 (en) 2007-10-03
ES2386461T3 (en) 2012-08-21
US20160159803A1 (en) 2016-06-09
JP2008540493A (en) 2008-11-20
US20170275288A1 (en) 2017-09-28
PL1881834T3 (en) 2012-09-28
AU2006245675A1 (en) 2006-11-16
IL186750A (en) 2014-08-31
US9708328B2 (en) 2017-07-18
MX2007014081A (en) 2008-02-12
WO2006120251A1 (en) 2006-11-16
BRPI0609101A2 (en) 2010-02-17
US20160158238A1 (en) 2016-06-09
US20140094468A1 (en) 2014-04-03
US9951075B2 (en) 2018-04-24
KR20080005978A (en) 2008-01-15
EP1881834B1 (en) 2012-04-25
US20090156595A1 (en) 2009-06-18
EP1881834A1 (en) 2008-01-30
ATE554772T1 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
IL186750A0 (en) Pteridines useful as hcv inhibitors and methods for the preparation thereof
SI1888580T1 (en) PYRIDO?á2,3-D?åPYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF
EP1906945A4 (en) Hcv inhibitors
EP1895838A4 (en) Compositions and methods
ZA200800256B (en) Antiviral compounds and methods
IL184111A0 (en) Prostaglandin-containing compositions and methods for enhancing the stability thereof
EP1960781A4 (en) Compositions and methods for detecting phosphomonoester
GB0522287D0 (en) Method and compositions
PL1922309T3 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
EP1877068A4 (en) Nicotinamide riboside kinase compositions and methods for using the same
IL189626A0 (en) Benzodiazepines as hcv inhibitors
IL184834A0 (en) Compositions and methods for the manufacture thereof
ZA200803283B (en) Pharmaceutical gallium compositions and methods
ZA200804299B (en) 3-amino-2-arylpropyl azaindoles and uses thereof
EP1893625A4 (en) Methods for the preparation of 9-deazapurine derivatives
GB0525957D0 (en) Methods
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
GB0524927D0 (en) Compositions and method
IL189210A0 (en) Methods for the preparation of hcv polymerase inhibitors
ZA200800672B (en) Introcatechol derivatives as COMT inhibitors
EP1901752A4 (en) Compositions and methods for viral inhibition
EP1838319A4 (en) Pde5 inhibitor compositions and methods for immunotherapy
GB0511235D0 (en) Compositions and method
GB0501348D0 (en) Compositions and methods
GB0715741D0 (en) Methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees